February 27, 2017 7:50am

 

While catalysts and milestone fulfillment are the keys to the short-term, so when and what are they?

 

Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

 

 

Expectation will be the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions through this year 2017.

 

Today’s headlights: Dow futures are DOWN -0.02% and NASDAQ futures are DOWN -0.11%

Indexes and ETFs: The IWM (-0.06%) is DOWN, the XBI (+0.40%) is UP and IBB and XLV are NOT indicated

 

 

U.S. stock index futures pointed to a flat open on Monday, as stocks tried to continue their recent record run.

European markets hovered around the flat line as the 31-billion dollar London Stock Exchange-Deutsche Boerse merger appeared to unravel.

Asia markets fell, with sterling tumbling nearly 0.4% to the dollar. Analysts pointed to a report from the Times of London that suggested Prime Minister Theresa May was preparing for the Scottish government to call a second independence referendum to coincide with the triggering of Article 50 in March.

Data docket: durable goods orders are expected at 8:30 am ET, while pending home sales are due at 10 am ET.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) closed NEGATIVE on Friday, Thursday, Wednesday and Tuesday while Monday was a holiday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

·         Friday closed NEGATIVE with 23 decliners, 17 advancers and 3 flats

·         Thursday – not tracked, family death,

·         Wednesday closed NEGATIVE with 27 decliners, 14 advancers and 2 flats;

·         Tuesday closed NEGATIVE with 21 decliners, 17 advancers and 5 flats;

·         Last Monday, the market was closed;

 

 

Remembering Friday’s closing bell newsletter, “The sector exposed its downside again.”

Reiterating, “The sector is out of gas, lacking GPS and a destination for their development programs. Investors aren’t hearing the stories of advancement as many clinical studies are about to blown away by small patient population data points making … a P2 or P3’s trial more about another maybe!”

​Be ready for the oversold ... to make some moves!

 

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

·         The iShares Nasdaq Biotechnology (IBB) closed  Friday up +0.20% and is NOT indicating in Monday’s pre-market;

·         The SPDR S&P Biotech ETF (XBI) closed Friday up +0.10% and is UP +0.40%  in Monday’s after-market;

·         The Health Care Select Sector SPDR ETF (XLV) closed up +0.48% Friday and is NOT indicating in Monday’s pre-market;

·         The iShares Russell 2000 (IWM) closed down -0.07% on Friday and is DOWN -0.06% in Monday’s pre-market

                                                                                   

 

Companies in my headlights:

Just getting back from family issues … on the plane in an hour

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.